EUVIMEDEUVIMED entdecken
Open Access

Utilization of a CMV T Cell Immunity Assay to Guide Secondary Prophylaxis in Solid Organ Transplant Recipients

Christina Doligalski iD, Luther Bartelt iD, Anne M Lachiewicz iD, Arlene C Seña iD, Mary Chandran iD

Transplant Infectious Disease · 2026

DOI: 10.1111/tid.70185 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant Infectious Disease, 2026. Verfasst von Christina Doligalski und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, UNC Health, Chapel Hill, North Carolina, USA. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, T-Lymphocytes, Cytomegalovirus, Antiviral Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Secondary prophylaxis following treatment of CMV infection in solid organ transplant recipients (SOTRs) may be considered in high‐risk SOTRs, although utilization criteria are not well described. The addition of CMV‐specific T‐cell immunity assay testing may help guide selection of SOTRs for secondary prophylaxis.

Methods

All SOTRs at a single center with CMV T‐cell assays obtained during secondary prophylaxis between January 2020 and August 2023 were reviewed. CMV antiviral secondary prophylaxis discontinuation rates and subsequent need for antiviral therapy re‐initiation were recorded. Positive predictive and negative predictive values of the assay, as well as the association between absolute lymphocyte count (ALC) and CMV T cell assay variables, were assessed.

Results

CMV T‐cell assay results in 32/78 (41%) SOTRs showed adequate response. Secondary prophylaxis was discontinued in 27 (84.4%) with adequate and 13 (28.2%) with inadequate T‐cell response ( p < 0.005). CMV DNAemia requiring re‐initiation of CMV therapy occurred in 2/27 (7.4%) of the adequate and 3/13 (23.1%) of the inadequate response cohorts ( p = 0.056), demonstrating a PPV and NPV of 92.6% and 23.1%, respectively, with 71.4% sensitivity and 60% specificity. When combined with ALC > 0.5 10 9 /L at time of assay, an adequate T cell assay response was significantly associated with no CMV reactivation ( n = 0/22, p < 0.001).

Conclusion

In this exploratory population, the combination of an adequate CMV T‐cell assay with adequate ALC was strongly predictive of no CMV reactivation. Further investigation into the predictive characteristics of a CMV T‐cell assay combined with ALC and other patient‐specific factors may optimize its clinical application. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytomegalovirus InfectionsT-LymphocytesCytomegalovirusAntiviral AgentsOrgan TransplantationSecondary PreventionHumansFemaleTransplant RecipientsMiddle AgedMaleAdultLymphocyte CountRetrospective StudiesBreakthrough InfectionsAgedPredictive Value of TestsDNA, Viral

Stichwörter der Autor:innen

CMVCMV T cell assayabsolute lymphocyte countsecondary prophylaxis

Substanzen

Antiviral AgentsDNA, Viral

Autor:innen und Institutionen

  • Department of Pharmacy, UNC Health, Chapel Hill, North Carolina, USA.
  • Department of Medicine, UNC Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.

ORCID-Profile: Christina Doligalski, Luther Bartelt, Anne M Lachiewicz, Arlene C Seña, Mary Chandran

Zitieren

APA

Doligalski, C., Bartelt, L., Lachiewicz, A. M., Seña, A. C., & Chandran, M. (2026). Utilization of a CMV T Cell Immunity Assay to Guide Secondary Prophylaxis in Solid Organ Transplant Recipients. Transplant Infectious Disease. https://doi.org/10.1111/tid.70185

Vancouver

Doligalski C, Bartelt L, Lachiewicz AM, Seña AC, Chandran M. Utilization of a CMV T Cell Immunity Assay to Guide Secondary Prophylaxis in Solid Organ Transplant Recipients. Transplant Infectious Disease. 2026. doi:10.1111/tid.70185

BibTeX
@article{Doligalski2026,
  author = {Doligalski, Christina and Bartelt, Luther and Lachiewicz, Anne M and Seña, Arlene C and Chandran, Mary},
  title = {Utilization of a CMV T Cell Immunity Assay to Guide Secondary Prophylaxis in Solid Organ Transplant Recipients},
  journal = {Transplant Infectious Disease},
  year = {2026},
  doi = {10.1111/tid.70185}
}
Kostenlos starten →